Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

1994 • 6,495 citations

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

1999 • 3,484 citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 • 1,652 citations

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

1999 • 878 citations

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

1997 • 638 citations

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

1997 • 584 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 576 citations

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

1995 • 447 citations

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

1996 • 410 citations

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

1987 • 360 citations

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

1996 • 336 citations

The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.

1988 • 305 citations

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

1998 • 300 citations

Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab

1999 • 296 citations

Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome

1998 • 275 citations

Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance

1999 • 269 citations

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

2000 • 267 citations

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

1993 • 221 citations

Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow

1994 • 182 citations

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon

1989 • 182 citations

The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas

1998 • 165 citations

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

1998 • 152 citations

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma

1996 • 140 citations

Treatment approaches to the low-grade lymphomas

1994 • 100 citations

Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma.

1993 • 86 citations

Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells

1992 • 83 citations

Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.

1995 • 46 citations